Ivabradine Stada 5 mg film-coated tablets EFG
Spain
Table of Contents
- Patient Information Leaflet
- Introduction
- 1. What Ivabradina Stada is and what it is used for
- How does Ivabradine work?
- 2. What you need to know before taking Ivabradina Stada
- 3. How to take Ivabradina Stada
- 4. Possible adverse effects
- 5. Storage of Ivabradine Stada
- 6. Contents of the pack and other information
- **Composition of Ivabradina Stada**
- **Appearance of the product and contents of the container**
Patient Information Leaflet
Introduction
Package Leaflet: Information for the Patient
Ivabradina Stada 5 mg Film-coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, because it may harm them.
- If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
Leaflet Contents:
- What Ivabradina Stada is and what it is used for
- What you need to know before taking Ivabradina Stada
- How to take Ivabradina Stada
- Possible side effects
- How to store Ivabradina Stada
- Contents of the pack and other information
1. What Ivabradina Stada is and what it is used for
Ivabradine is a heart medication used to treat:
- Symptomatic stable angina (which causes chest pain) in adult patients with a heart rate greater than or equal to 70 beats per minute. It is used in adult patients who cannot tolerate or are unable to take heart medications known as beta-blockers. It is also used in combination with beta-blockers in adult patients whose condition is not fully controlled with a beta-blocker alone.
- Chronic heart failure in adult patients with a heart rate greater than or equal to 75 beats per minute. It is used in combination with standard therapy, including treatment with beta-blockers, or when beta-blockers are contraindicated or not tolerated.
About stable angina (commonly known as "angina"):
Stable angina is a heart disease that occurs when the heart does not receive enough oxygen. It typically appears between the ages of 40 and 50. The most common symptom of angina is pain or discomfort in the chest. Angina is more likely to occur when the heart beats faster, such as during physical exertion, emotional stress, exposure to cold, or after eating. This increase in heart rate can trigger chest pain in people with angina.
About chronic heart failure:
Chronic heart failure is a heart condition that occurs when your heart cannot pump enough blood to meet the body's needs. The most common symptoms of heart failure are shortness of breath, fatigue, tiredness, and swelling of the ankles.
How does Ivabradine work?
Ivabradine works primarily by reducing the heart rate by several beats per minute. This reduces the heart's oxygen demand, particularly in situations where an angina attack is more likely to occur. Thus, ivabradine tablets help control and reduce the number of angina attacks.
Additionally, since elevated heart rate negatively affects heart function and vital prognosis in patients with chronic heart failure, the specific heart rate-lowering action of ivabradine helps improve heart function and vital prognosis in these patients.
2. What you need to know before taking Ivabradina Stada
Do not take Ivabradina tablets
- if you are allergic to ivabradine or to any of the other ingredients of this medicine (listed in section 6);
- if your resting heart rate before treatment is too slow (below 70 beats per minute);
- if you have cardiogenic shock (a heart condition treated in hospital);
- if you have a heart rhythm disorder;
- if you are having a heart attack;
- if you have very low blood pressure;
- if you have unstable angina (a severe type of angina in which chest pain occurs frequently, with or without exertion);
- if you have heart failure that has recently worsened;
- if your heart rate is solely controlled by a pacemaker;
- if you have severe liver problems;
- if you are taking medicines for fungal infections (such as ketoconazole, itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin, or erythromycin given orally), medicines for HIV infection (such as nelfinavir, ritonavir) or nefazodone (a medicine used to treat depression) or diltiazem, verapamil (used to treat high blood pressure or angina);
- if you are a woman of childbearing age and are not using reliable contraceptive methods;
- if you are pregnant or trying to become pregnant;
- if you are breastfeeding.
Warnings and precautions
Talk to your doctor or pharmacist before taking Ivabradina tablets:
- if you have heart rhythm disorders (such as irregular heartbeat, palpitations, increased chest pain) or persistent atrial fibrillation (a type of irregular heartbeat), or an abnormality on the electrocardiogram (ECG) known as “Long QT syndrome”;
- if you experience symptoms such as tiredness, dizziness, or shortness of breath (this may mean your heart is beating too slowly);
- if you develop symptoms of atrial fibrillation (unusually high resting pulse (over 110 beats per minute) or irregular pulse, without apparent reason, making it difficult to measure);
- if you have recently had a stroke (cerebral attack);
- if you have mild to moderate low blood pressure;
- if you have uncontrolled blood pressure, especially after a change in your antihypertensive treatment;
- if you have severe heart failure or heart failure with an ECG abnormality known as “bundle branch block”;
- if you have chronic retinal eye disease;
- if you have moderate liver problems;
- if you have severe kidney problems.
If any of these conditions apply to you, consult your doctor immediately before or during treatment with Ivabradina tablets.
Children
Ivabradina tablets are not intended for use in children and adolescents under 18 years of age.
Taking Ivabradina tablets with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Make sure to inform your doctor if you are taking any of the following medicines, as dose adjustment of Ivabradina tablets or monitoring may be necessary:
- fluconazole (an antifungal medicine);
- rifampicin (an antibiotic);
- barbiturates (for sleep disorders or epilepsy);
- phenytoin (for epilepsy);
- Hypericum perforatum or St. John’s wort (a herbal remedy for depression);
- Medicines that prolong the QT interval used to treat heart rhythm disorders or other conditions:
- quinidine, disopyramide, ibutilide, sotalol, amiodarone (for treating heart rhythm disorders);
- bepridil (for treating angina);
- certain types of medicines for treating anxiety, schizophrenia, or other psychoses (such as pimozide, ziprasidone, sertindole);
- antimalarial medicines (such as mefloquine or halofantrine);
- intravenous erythromycin (an antibiotic);
- pentamidine (an antiparasitic medicine);
- cisapride (for gastroesophageal reflux).
- Certain types of diuretics that may cause a decrease in blood potassium levels, such as furosemide, hydrochlorothiazide, indapamide (used to treat edema, high blood pressure).
Taking Ivabradina tablets with food and drinks
Avoid grapefruit juice during treatment with Ivabradina tablets.
Pregnancy and breastfeeding
Do not take Ivabradina tablets if you are pregnant or intend to become pregnant (see “Do not take Ivabradina tablets”).
If you are pregnant and have taken Ivabradina tablets, consult your doctor.
Do not take Ivabradina tablets if you are of childbearing age unless you are using reliable contraceptive methods (see “Do not take Ivabradina tablets”).
Do not take Ivabradina tablets if you are breastfeeding (see “Do not take Ivabradina tablets”). Speak with your doctor if you are breastfeeding or plan to breastfeed, as breastfeeding must be discontinued if you are taking Ivabradina tablets.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
Ivabradina tablets may cause transient luminous phenomena (a brief brightness in the visual field, see “Possible side effects”). If this occurs, be cautious when driving or operating machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; therefore, it is essentially “sodium-free”.
3. How to take Ivabradina Stada
Follow exactly the instructions given by your doctor or pharmacist for taking this medicine. If in doubt, consult your doctor or pharmacist again.
Ivabradina tablets should be taken with breakfast and dinner.
Ivabradina Stada 5 mg film-coated tablets may be divided into equal doses.
If you are being treated for stable angina
The starting dose should not exceed one 5 mg Ivabradina tablet twice daily. If you still have angina symptoms and if you have tolerated the 5 mg twice daily dose well, the dose may be increased. The maintenance dose should not exceed 7.5 mg twice daily. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (e.g. if you are elderly), your doctor may prescribe half the dose, i.e. half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet at night.
If you are being treated for chronic heart failure
The recommended starting dose is one 5 mg Ivabradina tablet twice daily, which may be increased if necessary to one 7.5 mg Ivabradina tablet twice daily. Your doctor will decide the appropriate dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (e.g. if you are elderly), your doctor may prescribe half the dose, i.e. half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet at night.
If you take more Ivabradina tablets than you should
An overdose of Ivabradina tablets may make you feel tired or cause difficulty breathing due to your heart beating too slowly. If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Ivabradina tablets
If you forget to take a dose of Ivabradina tablets, take the next dose at the scheduled time. Do not take a double dose to make up for forgotten doses.
If you stop taking Ivabradina tablets
Treatment for stable angina or chronic heart failure is usually lifelong; therefore, you should consult your doctor before stopping this medicine.
If you think that the effect of Ivabradina tablets is too strong or too weak, inform your doctor or pharmacist.
If you have any further questions about using this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Converted with the trial version of Word Cleaner Server Version, it will only convert 75% of a document. To remove this message click here to buy the full version now.
Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.
The most common adverse reactions with this medicine are dose-dependent and are related to its mechanism of action:
Adverse effects very common (may affect more than 1 in 10 people)
Luminous visual phenomena (brief episodes of increased brightness, almost always caused by sudden changes in light intensity). These may also be described as halos, flashes of color, image fragmentation, or multiple images. These usually occur during the first two months of treatment, after which they may recur and resolve during or after treatment.
Adverse effects common (may affect up to 1 in 10 people)
Changes in heart function (symptoms include slowed heart rate). This occurs especially during the first 2 to 3 months after starting treatment.
Other adverse effects that have been reported:
Adverse effects common (may affect up to 1 in 10 people)
- Rapid irregular heartbeat
- Sensation of abnormal heartbeat
- Uncontrolled blood pressure
- Headache
- Dizziness and blurred vision (cloudy vision)
Adverse effects uncommon (may affect up to 1 in 100 people)
- Palpitations and extra heartbeats
- Feeling of dizziness (nausea)
- Constipation
- Diarrhea
- Abdominal pain
- Sensation of spinning (vertigo)
- Difficulty breathing (dyspnea)
- Muscle cramps
- Changes in laboratory tests: elevated blood levels of uric acid, excess eosinophils (a type of white blood cell), and elevated blood creatinine levels (a muscle breakdown product)
- Skin rash
- Angioedema (such as swelling of the face, tongue, or throat, difficulty breathing or swallowing)
- Low blood pressure
- Fainting
- Feeling of tiredness
- Feeling of weakness
- Abnormal electrocardiogram
- Double vision
- Visual disturbance
Converted with the trial version of Word Cleaner Server Version, it will only convert 75% of a document. To remove this message click here to buy the full version now.
5. Storage of Ivabradine Stada
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging, after EXP. The expiry date refers to the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines must not be disposed of via wastewater or household waste. Dispose of empty containers and unused medicines at the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Ivabradina Stada
- The active substance is ivabradine (as hydrochloride).
Ivabradina Stada 5 mg: one film-coated tablet contains 5 mg of ivabradine (equivalent to 5.390 mg of ivabradine as hydrochloride).
- The other components are: Betadex, microcrystalline cellulose, sodium croscarmellose, magnesium stearate (core); hypromellose (HPMC 2910), lactose monohydrate, titanium dioxide (E171), macrogol 4000, iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172) (coating).
Appearance of the product and contents of the container
Ivabradina Stada 5 mg: film-coated tablets, round, pink in colour, approximately 8.7 mm in diameter, bevelled, marked with "I9VB" on one side and "5" on the other.
The tablets are supplied in PVC/PE/PVDC/Aluminum or Aluminum/Aluminum blister packs containing 14, 28, 28 (sample), 56, 98, 100 or 112 film-coated tablets.
Only certain pack sizes may be commercially available.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona), Spain
Manufacturer:
Synthon Hispania S.L.
C/Castelló nº1, Pol. Las Salinas
08830 Sant Boi de Llobregat (Barcelona)
Spain
or
Synthon BV
Microweg 22, Nijmegen
6545 CM
The Netherlands
or
Synthon s.r.o.
Brnenská 32/cp. 597
678 01 Blansko
Czech Republic
or
STADA Arzneimittel AG
Stadastrasse 2 - 18,
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Vienna
Austria
or
Clonmel Healthcare Ltd.
Waterford Road
Clonmel, Co. Tipperary
Ireland
or
Centrafarm Services B.V.
Van de Reijtstraat 31-E
4814 NE Breda
The Netherlands
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
AT Ivabradin Stada 5 mg Filmtabletten
DE Ivabradin AL 5 mg Filmtabletten
ES Ivabradina Stada 5 mg comprimidos recubiertos con película EFG
FR IVABRADINE EG 5 mg, comprimé pelliculé
IT IVABRADINA EG
NL Ivabradine CF 5 mg, filmomhulde tabletten
PT Ivabradina Ciclum
SI Ivabradin Stada 5 mg filmsko obložene tablete
SK Ivabradín Stada 5 mg filmom obalené tablety
Date of the most recent review of this leaflet: December 2021
Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS): http://www.aemps.gob.es/.